Quiros Juan Jose Chacon Sells 7,751 Shares of Establishment Labs (NASDAQ:ESTA) Stock

Establishment Labs Holdings Inc. (NASDAQ:ESTA) Director Quiros Juan Jose Chacon sold 7,751 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $70.48, for a total transaction of $546,290.48. Following the sale, the director owned 1,032,504 shares of the company’s stock, valued at approximately $72,770,881.92. This trade represents a 0.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Quiros Juan Jose Chacon also recently made the following trade(s):

• On Friday, May 1st, Quiros Juan Jose Chacon sold 67,249 shares of Establishment Labs stock. The stock was sold at an average price of $70.78, for a total transaction of $4,759,884.22.
• On Monday, April 27th, Quiros Juan Jose Chacon sold 2,180 shares of Establishment Labs stock. The stock was sold at an average price of $66.26, for a total transaction of $144,446.80.
• On Friday, April 24th, Quiros Juan Jose Chacon sold 30,178 shares of Establishment Labs stock. The stock was sold at an average price of $65.78, for a total transaction of $1,985,108.84.
• On Thursday, April 23rd, Quiros Juan Jose Chacon sold 42,642 shares of Establishment Labs stock. The stock was sold at an average price of $65.43, for a total transaction of $2,790,066.06.
• On Tuesday, April 14th, Quiros Juan Jose Chacon sold 37,500 shares of Establishment Labs stock. The stock was sold at an average price of $65.23, for a total value of $2,446,125.00.
• On Wednesday, March 25th, Quiros Juan Jose Chacon sold 3,575 shares of Establishment Labs stock. The stock was sold at an average price of $60.08, for a total value of $214,786.00.
• On Monday, March 23rd, Quiros Juan Jose Chacon sold 33,925 shares of Establishment Labs stock. The shares were sold at an average price of $60.39, for a total value of $2,048,730.75.

Establishment Labs Trading Up 0.0%

ESTA traded up $0.01 during trading on Monday, hitting $70.24. The company’s stock had a trading volume of 674,327 shares, compared to its average volume of 499,774. Establishment Labs Holdings Inc. has a twelve month low of $32.25 and a twelve month high of $83.31. The company has a quick ratio of 2.00, a current ratio of 3.04 and a debt-to-equity ratio of 10.51. The stock’s fifty day moving average price is $65.53 and its 200-day moving average price is $66.03. The firm has a market capitalization of $2.06 billion, a P/E ratio of -40.37 and a beta of 1.12.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.13. The firm had revenue of $64.62 million for the quarter, compared to analyst estimates of $63.80 million. Establishment Labs had a negative return on equity of 201.79% and a negative net margin of 24.19%.The company’s revenue was up 45.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.19) earnings per share. Analysts anticipate that Establishment Labs Holdings Inc. will post -0.86 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC raised its holdings in Establishment Labs by 1.2% during the second quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock worth $1,105,000 after buying an additional 299 shares during the last quarter. Brian Low Financial Group LLC raised its holdings in Establishment Labs by 10.2% during the first quarter. Brian Low Financial Group LLC now owns 4,598 shares of the company’s stock worth $261,000 after buying an additional 424 shares during the last quarter. Handelsbanken Fonder AB raised its holdings in Establishment Labs by 7.3% during the fourth quarter. Handelsbanken Fonder AB now owns 8,800 shares of the company’s stock worth $641,000 after buying an additional 600 shares during the last quarter. Swiss National Bank raised its holdings in shares of Establishment Labs by 1.8% in the fourth quarter. Swiss National Bank now owns 34,200 shares of the company’s stock valued at $2,492,000 after purchasing an additional 600 shares during the last quarter. Finally, Kestra Advisory Services LLC purchased a new stake in shares of Establishment Labs in the fourth quarter valued at about $47,000. Institutional investors and hedge funds own 72.91% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on ESTA shares. Needham & Company LLC increased their target price on shares of Establishment Labs from $84.00 to $86.00 and gave the stock a “buy” rating in a research note on Tuesday, February 24th. Canaccord Genuity Group increased their target price on shares of Establishment Labs from $85.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Wall Street Zen lowered shares of Establishment Labs from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. Stephens increased their target price on shares of Establishment Labs from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a research note on Friday, March 27th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $86.86.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.